切换至 "中华医学电子期刊资源库"

中华腔镜泌尿外科杂志(电子版) ›› 2024, Vol. 18 ›› Issue (04) : 386 -391. doi: 10.3877/cma.j.issn.1674-3253.2024.04.014

临床研究

尿液microRNA-326与腹腔镜根治性膀胱切除术治疗膀胱癌患者预后的相关性研究
刘中文1,(), 刘畅1, 高洋2, 刘东3, 林世庆4, 杨建华5, 赵福义6   
  1. 1. 618200 四川,绵竹市人民医院泌尿外科
    2. 618099 四川,德阳市中西医结合医院泌尿外科
    3. 618299 四川,绵竹市中医医院泌尿外科
    4. 621054 四川,绵阳市第三人民医院泌尿外科
    5. 641099 四川,内江市市中区人民医院泌尿外科
    6. 618099 四川,德阳市第六人民医院泌尿外科
  • 收稿日期:2023-11-02 出版日期:2024-08-01
  • 通信作者: 刘中文

Correlation of urinary microRNA-326 with the prognosis of bladder cancer patients treated with radical cystectomy

Zhongwen Liu1,(), Chang Liu1, Yang Gao2, Dong Liu3, Shiqing Lin4, Jianhua Yang5, Fuyi Zhao6   

  1. 1. Department of Urology, Mianzhu People's Hospital, Sichuan 618200, China
    2. Department of Urology, Deyang Hospital of Traditional Chinese and Western Medicine, Sichuan 618099, China
    3. Department of Urology, Mianzhu City Chinese Medicine Hospital, Sichuan 618299, China
    4. Department of Urology, the Third Hospital of Mianyang, Sichuan 621054, China
    5. Department of Urology, Neijiang Central District People's Hospital, Sichuan 641099, China
    6. Department of Urology, The Sixth People's Hospital of Deyang City, Sichuan 618099, China
  • Received:2023-11-02 Published:2024-08-01
  • Corresponding author: Zhongwen Liu
引用本文:

刘中文, 刘畅, 高洋, 刘东, 林世庆, 杨建华, 赵福义. 尿液microRNA-326与腹腔镜根治性膀胱切除术治疗膀胱癌患者预后的相关性研究[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(04): 386-391.

Zhongwen Liu, Chang Liu, Yang Gao, Dong Liu, Shiqing Lin, Jianhua Yang, Fuyi Zhao. Correlation of urinary microRNA-326 with the prognosis of bladder cancer patients treated with radical cystectomy[J/OL]. Chinese Journal of Endourology(Electronic Edition), 2024, 18(04): 386-391.

目的

探究尿液中微小核糖核酸-326(miR-326)与腹腔镜根治性膀胱切除术治疗膀胱癌患者预后的相关性。

方法

选择2017年1月至2019年2月在绵竹市人民医院、德阳市中西医结合医院、绵竹市中医医院、绵阳市第三人民医院、内江市市中区人民医院、德阳市第六人民医院行根治性膀胱切除术治疗的138例膀胱癌患者作为研究对象,随访6~60个月,根据其生存状态将其分为生存组(n=95)和死亡组(n=43)。用实时荧光定量PCR法检测尿液中miR-326水平。用受试者工作特征(ROC)曲线评价miR-326判断膀胱癌患者预后的价值,用Kaplan-Meier和Log-rank比较不同miR-326水平患者的生存情况,用Cox回归分析膀胱癌患者预后的风险因素。

结果

生存组的年龄、T4期占比和淋巴结转移占比均低于死亡组(P值均<0.05)。两组的术后miR-326水平均高于术前(P值均<0.05)。生存组的术前miR-326水平高于死亡组,miR-326变化值低于死亡组(P值均<0.05)。术前miR-326判断膀胱癌患者预后的ROC曲线下面积高于miR-326变化值(P<0.05)。术前miR-326≤0.40患者的生存率低于术前miR-326>0.40患者(P<0.05)。Cox回归分析结果显示高龄和高T分期是膀胱癌预后的独立危险因素,高术前miR-326是膀胱癌预后的独立保护因素(P值均<0.05)。

结论

根治性膀胱切除术前miR-326水平高提示膀胱癌患者预后不良风险低。

Objective

To investigate the correlation between microRNA-326 (miR-326) in urine and the prognosis of bladder cancer patients treated with radical cystectomy.

Methods

138 patients with bladder cancer treated with radical cystectomy at Mianzhu People's Hospital, Deyang Hospital of Traditional Chinese and Western Medicine, Mianzhu City Chinese Medicine Hospital, the Third Hospital of Mianyang, Neijiang Central District People's Hospital, the Sixth People's Hospital of Deyang City, from January 2017 to February 2019 were selected as study subjects, followed up for 6 to 60 months, and divided into survival (n=95) and death (n=43) groups according to their survival status. Real-time fluorescence quantitative PCR was used to detect miR-326 levels in urine. Receiver operating characteristic (ROC) curve was used to evaluate the value of miR-326 in determining the prognosis of bladder cancer patients. Kaplan-Meier and log-rank were used to compare the survival of patients with different miR-326 level, and Cox regression was used to analyse the risk factors for the prognosis of bladder cancer patients.

Results

Age, proportion of T4 stage and proportion of lymph node metastases were lower in the survival group than in the death group (all P<0.05). Postoperative miR-326 levels were higher in both groups than preoperatively (all P<0.05). Preoperative miR-326 level was higher in the survival group than in the death group, and the miR-326 change value was lower than in the death group (all P<0.05). The area under the ROC curve for pre-operative miR-326 to determine the prognosis of bladder cancer patients was higher than the miR-326 change value (P<0.05). Patients with preoperative miR-326≤0.40 had a lower survival rate than patients with preoperative miR-326>0.40 (P<0.05). Cox regression analysis showed that age and T-stage were independent risk factors for bladder cancer prognosis, and preoperative miR-326 was an independent protective factor for bladder cancer prognosis (all P<0.05).

Conclusion

High miR-326 levels before radical cystectomy suggest a low risk of poor prognosis in patients with bladder cancer.

表1 两组膀胱癌患者临床资料比较
表2 两组膀胱癌患者尿液miR-326水平比较
图1 尿液miR-326判断膀胱癌患者预后的ROC曲线
图2 不同尿液miR-326水平的膀胱癌患者的生存曲线
表3 膀胱癌患者预后风险因素Cox回归分析赋值
表4 膀胱癌患者预后风险因素的Cox回归分析结果
[1]
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424.
[2]
中国肿瘤医院泌尿肿瘤协作组. 中国膀胱癌保膀胱治疗多学科诊治协作共识[J]. 中华肿瘤杂志, 2022, 44(3): 209-218.
[3]
Lenis AT, Lec PM, Chamie K, et al. Bladder cancer: a review[J]. JAMA, 2020, 324(19): 1980-1991.
[4]
Parizi PK, Yarahmadi F, Tabar HM, et al. MicroRNAs and target molecules in bladder cancer[J]. Med Oncol, 2020, 37(12): 118.
[5]
Wei B, Wang Z, Lian Q, et al. hsa_circ_0139402 promotes bladder cancer progression by regulating hsa-miR-326/PAX8 signaling[J]. Dis Markers, 2022, 2022: 9899548.
[6]
刘振华,李向东,刘泽赋,等. 单中心1041例膀胱癌根治尿流改道患者手术疗效和并发症[J]. 中山大学学报(医学科学版), 2022, 43(5): 818-827.
[7]
曹振学, 郭园园, 刘贝贝, 等. MiR-15a与临床膀胱癌患者术后复发的相关性分析[J]. 中华全科医学, 2021, 19(4): 547-549, 647.
[8]
Tang Q, Chen Z, Zhao L, et al. Circular RNA hsa_circ_0000515 acts as a miR-326 sponge to promote cervical cancer progression through up-regulation of ELK1[J]. Aging, 2019, 11(22): 9982-9999.
[9]
Nie FR, Li QX, Wei HF, et al. MiR-326 inhibits the progression of papillary thyroid carcinoma by targeting MAPK1 and ERBB4[J]. Neoplasma, 2020, 67(3): 604-613.
[10]
Moya L, Meijer J, Schubert S, et al. Assessment of miR-98-5p, miR-152-3p, miR-326 and miR-4289 expression as biomarker for prostate cancer diagnosis[J]. Int J Mol Sci, 2019, 20(5): 1154.
[11]
Bao Z, Gao S, Tang Q, et al. A novel role of miR-326 in colorectal carcinoma by regulating E2F1 expression[J]. J BUON, 2021, 26(2): 528-535.
[12]
Zhang Y, Chen L, Luo G. Long non-coding RNA PCAT6 regulates bladder cancer progression via the microRNA-143-3p/PDIA6 axis[J]. Exp Ther Med, 2021, 22(3): 947.
[13]
Xia W, Chen C, Zhang MR, et al. LncRNA PCAT6 aggravates the progression of bladder cancer cells by targeting miR-513a-5p[J]. Eur Rev Med Pharmacol Sci, 2020, 24(19): 9908-9914.
[14]
Zhang D, Du D, Yi S, et al. LncRNA PCAT6: a potential biomarker for diagnosis and prognosis of bladder cancer[J]. Ann Diagn Pathol, 2020, 49: 151642.
[15]
Luo J, Zheng J, Hao W, et al. LncRNA PCAT6 facilitates cell proliferation and invasion via regulating the miR-326/hnRNPA2B1 axis in liver cancer[J]. Oncol Lett, 2021, 21(6): 471.
[16]
Liu B, Jiang H Y, Yuan T, et al. Enzalutamide-induced upregulation of PCAT6 promotes prostate cancer neuroendocrine differentiation by regulating miR-326/HNRNPA2B1 axis[J]. Front Oncol, 2021, 11: 650054.
[17]
Tu J, Wu F, Chen L, et al. Long non-coding RNA PCAT6 induces M2 polarization of macrophages in cholangiocarcinoma via modulating miR-326 and RhoA-ROCK signaling pathway[J]. Front Oncol, 2020, 10: 605877.
[18]
Zhu Q, Wang S, Shi Y. LncRNA PCAT6 activated by SP1 facilitates the progression of breast cancer by the miR-326/LRRC8E axis[J]. Anticancer Drugs, 2022, 33(2): 178-190.
[19]
Lai C, Wu Z, Shi J, et al. Autophagy-related long noncoding RNAs can predict prognosis in patients with bladder cancer[J]. Aging, 2020, 12(21): 21582-21596.
[20]
王逸秋, 沈文浩, 张瑞赟, 等. 前白蛋白水平对行根治性膀胱切除术的膀胱癌患者预后的预测价值[J]. 上海医学, 2021, 44(7): 496-500.
[21]
周佳维, 汪雄, 沈德贇, 等. 中性粒淋巴细胞比值与血小板淋巴细胞比值对腹腔镜膀胱癌根治术后肌层浸润性膀胱癌患者预后的预测价值[J]. 临床泌尿外科杂志, 2022, 37(2): 104-108.
[22]
杜光辉, 付志刚, 薛敏敏. 膀胱癌发病危险因素及与PET-CT辐射的相关性[J]. 实用癌症杂志, 2021, 36(11): 1904-1908.
[23]
符海能, 梁培育, 王声兴, 等. 术前临床实验室指标对肌层浸润性膀胱癌根治术后疗效及预后的影响[J]. 国际检验医学杂志, 2023, 44(10): 1167-1171.
[24]
裴德龙, 颜凯, 龚卓, 等. 不同尿流改道方式对46例老年膀胱癌患者手术并发症的影响[J]. 延边大学医学学报, 2021, 44(4): 269-273.
[25]
斯热努尔·艾合买提, 张瑞丽, 魏媛, 等. 肌层浸润性膀胱癌患者根治术后预后相关因素分析[J]. 现代肿瘤医学, 2020, 28(17): 2995-2999.
[1] 张晓宇, 殷雨来, 张银旭. 阿帕替尼联合新辅助化疗对三阴性乳腺癌的疗效及预后分析[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 346-352.
[2] 杨桂清, 孟静静. 哺乳期亚临床乳腺炎的研究进展[J/OL]. 中华乳腺病杂志(电子版), 2024, 18(06): 376-379.
[3] 许杰, 李亚俊, 韩军伟. 两种入路下腹腔镜根治性全胃切除术治疗超重胃癌的效果比较[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 19-22.
[4] 高杰红, 黎平平, 齐婧, 代引海. ETFA和CD34在乳腺癌中的表达及与临床病理参数和预后的关系研究[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 64-67.
[5] 李代勤, 刘佩杰. 动态增强磁共振评估中晚期低位直肠癌同步放化疗后疗效及预后的价值[J/OL]. 中华普外科手术学杂志(电子版), 2025, 19(01): 100-103.
[6] 屈翔宇, 张懿刚, 李浩令, 邱天, 谈燚. USP24及其共表达肿瘤代谢基因在肝细胞癌中的诊断和预后预测作用[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 659-662.
[7] 顾雯, 凌守鑫, 唐海利, 甘雪梅. 两种不同手术入路在甲状腺乳头状癌患者开放性根治性术中的应用比较[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 687-690.
[8] 付成旺, 杨大刚, 王榕, 李福堂. 营养与炎症指标在可切除胰腺癌中的研究进展[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 704-708.
[9] 李伟, 宋子健, 赖衍成, 周睿, 吴涵, 邓龙昕, 陈锐. 人工智能应用于前列腺癌患者预后预测的研究现状及展望[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 541-546.
[10] 庞名扬, 魏勇, 沈露明, 朱清毅. 运用国产单孔机器人完成经膀胱入路膀胱部分切除术治疗膀胱癌一例报道[J/OL]. 中华腔镜泌尿外科杂志(电子版), 2024, 18(06): 638-643.
[11] 陈樽, 王平, 金华, 周美玲, 李青青, 黄永刚. 肌肉减少症预测结直肠癌术后切口疝发生的应用研究[J/OL]. 中华疝和腹壁外科杂志(电子版), 2024, 18(06): 639-644.
[12] 关小玲, 周文营, 陈洪平. PTAAR在乙肝相关慢加急性肝衰竭患者短期预后中的预测价值[J/OL]. 中华肝脏外科手术学电子杂志, 2024, 13(06): 841-845.
[13] 韩加刚, 王振军. 梗阻性左半结肠癌的治疗策略[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 450-458.
[14] 王景明, 王磊, 许小多, 邢文强, 张兆岩, 黄伟敏. 腰椎椎旁肌的研究进展[J/OL]. 中华临床医师杂志(电子版), 2024, 18(09): 846-852.
[15] 郭曌蓉, 王歆光, 刘毅强, 何英剑, 王立泽, 杨飏, 汪星, 曹威, 谷重山, 范铁, 李金锋, 范照青. 不同亚型乳腺叶状肿瘤的临床病理特征及预后危险因素分析[J/OL]. 中华临床医师杂志(电子版), 2024, 18(06): 524-532.
阅读次数
全文


摘要